Skip To Main Content
Jérôme Cornillon on Muck Rack

Jérôme Cornillon

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Jérôme Cornillon’s profile

Articles by Jérôme Cornillon

GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS

|
By Tereza Coman, Stephane Morisset, Raynier Devillier, Maud D’Aveni, Frédéric Baron, Jacques Olivier Bay, Jean El-Cheikh, Claude-Eric Bulabois, Cristina Castilla-Llorente, Patrice Ceballos, Yves Chalandon, Sylvain Chantepie, Magalie Joris, Patrice Chevallier, Mustafa Alani, Jérôme Cornillon, Edouard Forcade, Gaelle Guillerm, Helene Labussière, Philippe Lewalle, Johan Maertens, Florent Malard, Jean-Valère Malfuson, Natacha Maillard, Jean Baptiste Mear, Stéphanie Nguyen-Quoc, Xavier Poiré, Marie-Thérèse Rubio, Felipe Suarez, Pascal Turlure, Alban Villate, Ibrahim Yakoub-Agha, Nicole Raus, Marie Robin, Anne Huynh, Mauricette Michallet, Karine Bilger, Etienne Daguindeau, Chama Mokeddem, Mikael Loschi, Cécile Pivert
| Nature Verified
Abstract Post-transplant cyclophosphamide (PTCy) has transformed graft-versus-host disease (GVHD) prophylaxis but its role in matched-donor reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) remains uncertain.
Open in Who Shared Issue with article?

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry

|
By Maël Heiblig, Zofia Gross, Amine Belhabri, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Martin Carré, Adrien Contejean, Clémence Santana, Clément Rocher Verified, Sylvain Lamure, Mauricette Michallet, Jérôme Cornillon, Mathieu Meunier, Natacha Mauz, Ugo Thevenet, Arthur Dony, Grégoire Le Meur, Emmanuel Beillard, Delphine Manzoni, Thomas Tassin, Sarah Huet, Adriana Plesa, Gaspar Requena Aspas, Gian-Matteo Pica, Samy Chraibi, Lucie Coster, Sylvie Tondeur, Serge Carillo, Pascale Flandrin
| Nature Verified
Abstract Measurable residual disease (MRD) is a key prognostic marker in acute myeloid leukemia (AML), but its significance in patients treated with azacitidine and venetoclax (AZA/VEN) outside clinical trials remains unclear. We retrospectively analyzed 220 newly diagnosed AML patients from the French VENAURA registry who achieved composite complete remission and underwent MRD evaluation by multiparametric flow cytometry (MFC, LAIP/LSC) and/or NPM1 RT-qPCR.
Open in Who Shared Issue with article?

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC

|
By Matthieu Jestin, Sébastien Maury, Anne Huynh, Edouard Forcade, Micha Srour, Cristina Castilla-Llorente, Jean-Baptiste Mear, Sylvain Chantepie, Dominik Schneidawind, Jakob Passweg, Claude-Eric Bulabois, Jérôme Cornillon, Michael Loschi, Jean-Valère Malfuson, Eolia Brissot, Pascal Turlure, Xavier Poiré, Carlos Graux, Nicole Raus, Alban Villate, Etienne Daguindau, Yves Chalandon, Gaelle Guillerm, Jacques-Olivier Bay, Clémence Loiseau, Natacha Maillard, Raynier Devillier, Marie-Thérèse Rubio, Franciane Paul, Sylvie François, Patrice Chevallier, Hélène Labussiere-Wallet, Hervé Dombret, Stephanie Nguyen, Nicolas Boissel, Nathalie Dhedin, Mustafa Alani, Véronique Lhéritier, Karin Bilger
| Nature Verified
In myeloablative HLA-matched hematopoietic stem cell transplantation (HSCT) peripheral blood stem cells (PBSC) increase the risk of chronic graft-versus-host disease (cGVHD) compared to bone marrow (BM) [1, 2]. While cGVHD is associated with substantial morbidity, it may also augment graft-versus-leukemia activity.
Open in Who Shared Issue with article?

Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure

|
By Johannes Clausen, Martin Carré, David Michonneau, Alexander Schauwvlieghe, Pedro Asensi Cantó, Sylvie François, Ludovic Gabellier, Lucía López Corral, Ana Benzaquén, Hélène Labussiere-Wallet, Jérôme Cornillon, Raynier Devillier, Anne Huynh, Pascal Turlure, Imi Faghmous, Florent Malard, Mohamad Mohty Verified, Cristina Castilla-Llorente, Anna Bauhofer, Hervé Jullien de Pommerol, Marion Bruelle, Behzad Kharabi Masouleh, Emilie Plantamura
| Nature Verified
Abstract CHRONOS is a multicenter, retrospective, cohort study involving acute graft-versus-host disease (aGvHD) adult patients with gastrointestinal (GI) symptoms, steroid- and ruxolitinib refractory, who initiated third-line therapy between 30 May 2019 and 30 September 2024. Primary endpoints were all-organ overall response rate (ORR) and GI-specific ORR (GI-ORR) around 28 days after treatment initiation.
Open in Who Shared Issue with article?

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group

|
By Gaspar Aspas Requena, Zofia Gross, Emmanuelle Tavernier, Pedro Chorão, Martin Carré, Adrien Contejean, Sylvain Lamure, Arthur Dony, Mauricette Michallet, Amine Belhabri, Maël Heiblig, Urbain Tauveron-Jalenques, Jérôme Cornillon, Clémence Santana, Natacha Mauz, Ugo Thevenet, Nadine Boullanger, Gian Matteo Pica
| Nature Verified
Abstract Fit relapsed/refractory (R/R) acute myeloid leukemia (AML) patients usually undergo intensive chemotherapy (IC)-based salvage to bridge them to allogeneic hematopoietic stem cell transplantation (HSCT), but their prognosis remains poor. Azacitidine and venetoclax (AZA/VEN) are increasingly used as salvage therapy in R/R AML with encouraging results, although data remain limited.
Open in Who Shared Issue with article?
Show More